Orchestra BioMed (NASDAQ:OBIO – Get Free Report)‘s stock had its “buy” rating reiterated by Chardan Capital in a research report issued on Thursday, Benzinga reports. They presently have a $20.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 277.00% from the stock’s previous close.
Separately, Jefferies Financial Group initiated coverage on Orchestra BioMed in a research report on Friday, January 19th. They issued a “buy” rating and a $14.00 price target for the company.
Read Our Latest Stock Report on OBIO
Orchestra BioMed Price Performance
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the company. Perceptive Advisors LLC purchased a new position in Orchestra BioMed in the first quarter worth $44,585,000. Vanguard Group Inc. grew its stake in Orchestra BioMed by 548.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,246,109 shares of the company’s stock worth $10,866,000 after buying an additional 1,053,937 shares during the last quarter. BlackRock Inc. acquired a new position in Orchestra BioMed during the 1st quarter valued at about $13,790,000. Geode Capital Management LLC purchased a new stake in Orchestra BioMed in the first quarter valued at about $2,446,000. Finally, State Street Corp raised its stake in Orchestra BioMed by 314.9% in the second quarter. State Street Corp now owns 141,837 shares of the company’s stock valued at $993,000 after buying an additional 107,651 shares during the last quarter. Institutional investors own 53.55% of the company’s stock.
Orchestra BioMed Company Profile
Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
See Also
- Five stocks we like better than Orchestra BioMed
- What is Insider Trading? What You Can Learn from Insider Trading
- Delta Airline’s Put Option Activity Isn’t Bad News
- The Role Economic Reports Play in a Successful Investment Strategy
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
- Consumer Staples Stocks, Explained
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.